Results 1 to 10 of about 10,598 (216)
Cancer Research, Statistics, and Treatment, 2021 Lung cancer diagnostics and therapeutics have witnessed a paradigm shift in the last decade because of the discovery of targetable biomarkers and rapid approvals of the corresponding targeted therapies.
Ullas Batra +2 more
doaj +2 more sources
NTRK fusion protein expression is absent in a large cohort of diffuse large B-cell lymphoma [PDF]
Frontiers in Oncology, 2023 BackgroundEven though two NTRK-targeting drugs are available for the treatment of irresectable, metastatic, or progressive NTRK-positive solid tumors, less is known about the role of NTRK fusions in lymphoma.
Susanne Ghandili +4 more
doaj +2 more sources
Cancer Medicine, 2022 TRK fusions are rare but targetable mutations which occur across a wide variety of cancer types. We report the prevalence of approximately 0.7% for NTRK‐positive colorectal cancer (CRC) by genetically profiling 2519 colonic and rectal tumors.
Misako Nagasaka +2 more
exaly +2 more sources
NTRK fusions and concomitant immune and genomic landscape detected by DNA and RNA comprehensive genomic profiling in a large healthcare system [PDF]
Frontiers in MedicineIntroductionThe use of next-generation sequencing (NGS) in clinical investigations has enabled the identification of actionable biomarkers across tumor histologies, paving the way for the development of pan-tumor therapies.
Alexa K. Dowdell +18 more
doaj +2 more sources
Cancer MedicineBackground Members of the neurotrophic tropomyosin receptor kinase (NTRK) gene family, NTRK1, NTRK2, and NTRK3 encode TRK receptor tyrosine kinases. Intra‐ or inter‐chromosomal gene rearrangements produce NTRK gene fusions encoding fusion proteins which ...
Shinji Kohsaka, Eiji Nakata
exaly +2 more sources
Сибирский онкологический журнал, 2022 Background. The first-generation trk inhibitors, larotrectinib and entrectinib, were approved by the u.s. Food and drug administration (Fda) for the treatment of advanced solid tumors harboring NTRK gene fusions in November 2018 and in august 2019 ...
A. A. Kechin +2 more
doaj +1 more source
PLoS ONE, 2022 The clinical profiles and outcomes of patients with neurotrophic tropomyosin receptor kinase fusion-positive (NTRK+) solid tumors receiving standard of care other than tropomyosin receptor kinase inhibitor (TRKi) targeted therapy have not been well ...
Derrek P Hibar +6 more
doaj +1 more source
The Ewha Medical Journal, 2021 Over the past decade, substantial advances have been made in the individualization of therapeutic strategies for metastatic colorectal cancer (mCRC).
doaj +1 more source
Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease
Drugs in Context, 2022 Oncogene addiction in non-small-cell lung cancer (NSCLC) has profound diagnostic and therapeutic implications. ALK, ROS1 and NTRK rearrangements are found in about 2–7%, 1–2% and 0.2% of unselected NSCLC samples, respectively; however, their frequency is
Daniele Marinelli +4 more
doaj +1 more source
Prevalence and clinico-genomic characteristics of patients with TRK fusion cancer in China
npj Precision Oncology, 2023 Neurotrophic tyrosine kinase (NTRK) fusions involving NTRK1, NTRK2, and NTRK3 were found in a broad range of solid tumors as driver gene variants. However, the prevalence of NTRK fusions in Chinese solid tumor patients is rarely reported.
Yujun Xu +12 more
doaj +1 more source